Injury Induced by Chemical Warfare Agents: Characterization and Treatment of Ocular Tissues Exposed to Nitrogen Mustard

Eyal Banin, Yair Morad, Eduard Berenshtein, Alexey Obolensky, Claudia Yabalon, Jacob Goldich, Fatim M. Adibelli, Gladys Zuniga, Maribel DeAnda, Jacob Pe'er, and Mordechai Chevion

PURPOSE. Mustard agents are highly toxic and abundant warfare chemicals, primarily affecting ocular tissues, with no specific treatment antidote. The purpose of the present study was to examine the efficacy of novel metallocomplexes, known to inhibit the formation of highly reactive free radicals, to reduce ocular injury induced by nitrogen mustard (NM).

METHODS. One eye in each of 72 rabbits was exposed to 1% to 2% NM. Topical treatment with eye drops of a metallocomplex—either zinc- or gallium-desferrioxamine (Zn/DFO or Ga/DFO)—was compared with treatment with saline, zinc (chloride), or DFO alone. Examiners masked to the treatment groups assessed the extent of ocular injury and the response to treatment using clinical, histologic, and biochemical criteria.

RESULTS. Exposure to NM followed by administration of carrier alone (saline) caused severe and long-lasting injury to ocular anterior segment structures. Treatment with either Zn/DFO or Ga/DFO yielded marked protection (52%–64%), including faster healing of corneal epithelial erosions, less scarring and neovascularization, decreased inflammation in the anterior chamber, better maintenance of intraocular pressure, and less severe changes in the iris and lens. These were also associated with better preservation of systemic antioxidant status. Zinc or DFO alone afforded lower levels of protection. No toxic effects of these complexes were observed.

CONCLUSIONS. It is suggested that Zn/DFO or Ga/DFO, by virtue of their enhanced ability to infiltrate cells and inhibit transition metal-dependent formation of free radicals through the combined push–pull mechanism, be considered as a basis for treatment of mustard injuries. (Invest Ophthalmol Vis Sci. 2003;44:2966–2972) DOI:10.1167/iovs.02-1164

Mustard agents are among the most powerful tactical chemical weapons that exist today. Sulfur mustard was first used in Ypres, Belgium, in World War I, and throughout the war, approximately 1,200,000 soldiers were exposed to it. Approximately one third of them required prolonged medical treatment for dermal, gastrointestinal, respiratory, and ocular injuries. More recently, mustard was used in the Iran-Iraq conflict against Kurdish civilians and Iranian troops. In view of the recent surge in international terror activity, the relative abundance of this weapon and the ease of its production and deployment raise the concern that it could be used by terrorists, as well as on the battlefield.

Incapacitating short- and long-term ocular injuries are major manifestations of mustard toxicity, affecting up to 90% of those exposed. Approximately 10% of Iranian mustard casualties exhibited ocular injuries that persisted for several months, despite treatment. Indeed, reports of delayed keratopathy in veterans of this war have recently appeared.

Generally, exposure to mustard agents produces eye inflammation to varying degrees. Although the toxic chemical reacts rapidly with ocular tissues after contact, discomfort and injury are usually delayed for hours. Symptoms begin with eye pain, photophobia, excessive tearing, and blurred vision. Physical findings include spasm of the eyelids, swelling and edema of skin and tissues around the eyes, conjunctival injection, and inflammation of the anterior chamber of the eye. The intraocular pressure (IOP) may increase and remain elevated for a few days. After several hours, the corneal epithelium begins to form vesicles and slough. In severely injured eyes, there is constriction of the pupils, dilatation of blood vessels within the iris, hemorrhages, and necrosis. Chemical anterior uveitis develops, leading to adhesions of the iris to the lens capsule with ensuing cataract formation. Late sequelae include corneal scarring and neovascularization as well as severe and chronic elevation of IOP due to neovascular glaucoma.

Strong evidence indicates that mustard injury is mediated, at least in part, by the formation and action of reactive oxygen species (ROS), in addition to its action as an alkylating agent. This notion is supported by the findings of a dramatic increase (30-fold) in copper levels and a decrease in ascorbic acid within the anterior chamber after ocular exposure to mustard compounds, both being indicators of oxidative stress. Free radicals have also been shown to play a role in corneal inflammation after exposure to other ocular irritants, such as alkali substances. In such cases, tissue damage after corrosive injury to the cornea is exacerbated by penetration of ROS to the corneal stroma, because they fragment DNA chains, polymerize or depolymerize proteins and hyaluronate, and destroy lipid membranes. ROS, such as the superoxide anion, reduce ferric iron (Fe3+) and copper (Cu2+) and produce the highly reactive hydroxyl radicals, Fe2+ and Cu+. These reduced metal ions, in turn, can react with H2O2 to produce the hydroxyl radical, which causes further damage. If indeed the formation of ROS is part of the pathogenesis of mustard-induced injury, curbing their formation could be highly beneficial.
Zinc desferrioxamine (Zn/DFO) and gallium desferrioxamine (Ga/DFO) are novel metal complexes that inhibit the catalysis of iron (and copper) in the formation of free radicals. Their protective activity can be visualized through the “pulling” out of redox active iron that is responsible for the production of the hydroxyl radicals through chelation by the DFO component. At the same time, the relatively inert zinc (or gallium) ion that is liberated during the exchange of iron within the complex, further acts as a secondary antioxidant, by “pushing” out additional iron ions from their catalytic binding sites. 11,12 The spatial structure of these complexes is markedly different from that of desferrioxamine alone, enhancing its ability to infiltrate cells and tissues. 12 In previous studies, we have shown that systemic treatment with Zn/DFO and Ga/DFO reduces damage to the retina subjected to ischemia and reperfusion, in accord with their enhanced infiltration through the blood-retinal barrier. 13,14 Similarly, topical application of Zn/DFO reduces corneal damage after alkali burn. 15 We therefore sought to examine the effectiveness of topical application of Zn/DFO and Ga/DFO in reducing ocular damage after exposure to nitrogen mustard (NM).

METHODS

Animal Model of Ocular NM Injury

Seventy-six New Zealand Albino rabbits weighing 2.5 to 3.5 kg were used. All animal experiments were conducted in compliance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. Animals were anesthetized with ketamine HCl (50 mg/kg) injected intramuscularly in combination with the relaxing agent xylazine (5.0 mg/kg). Local anesthetic drops (benoxinate HCl 0.4%; Fischer Pharmaceuticals, Tel-Aviv, Israel) at a concentration of 3.5 mM in saline; Zn/DFO and Ga/DFO were prepared by dissolving the chloride salt of the metal in doubly distilled water, maintaining pH at 3, and adding DFO at an equivalent concentration, followed by titration to pH 7.4 with sodium bicarbonate. The stock was diluted in saline to a final concentration of 3.5 mM, based on DFO concentration.

<table>
<thead>
<tr>
<th>Group</th>
<th>1a</th>
<th>1b</th>
<th>2a</th>
<th>2b</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
</tr>
</thead>
<tbody>
<tr>
<td>NM(%)</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>None</td>
<td>2</td>
</tr>
<tr>
<td>Saline</td>
<td>Saline</td>
<td>Zn/DFO</td>
<td>Zn/DFO</td>
<td>ZnCl₂</td>
<td>DFO</td>
<td>Saline</td>
<td>Ga/DFO</td>
<td></td>
</tr>
<tr>
<td>Eyes (n)</td>
<td>12</td>
<td>8</td>
<td>12</td>
<td>8</td>
<td>12</td>
<td>12</td>
<td>8</td>
<td>8</td>
</tr>
</tbody>
</table>

* NM, nitrogen mustard concentration (wt/vol %).
† Treatment, the type of treatment drops used in each group; Saline, normal saline; Zn/DFO, zinc desferrioxamine; Ga/DFO, gallium desferrioxamine, both at a concentration of 3.5 mM; ZnCl₂, zinc chloride (Aldrich Chemical Company, Inc., Milwaukee WI) at a concentration of 3.5 mM; DFO, Desferrioxamine (Desferal; Ciba-Geigy LTD, Basel, Switzerland) at a concentration of 3.5 mM in saline; Zn/DFO and Ga/DFO were prepared by dissolving the chloride salt of the metal in doubly distilled water, maintaining pH at 3, and adding DFO at an equivalent concentration, followed by titration to pH 7.4 with sodium bicarbonate.

Follow-up Parameters

Magnitude of ocular injury and response to treatment were assessed by examiners masked to the treatment groups. Repeated slit lamp examinations with scoring of anterior segment injury, measurements of IOP, color photographs of the anterior segment, fluorescein angiography (FA), electroretinography (ERG), and blood testing of antioxidant status were performed according to the following timetable and guidelines.

Slit Lamp Examinations. These were performed at 24 hours after injury and then repeated at 3, 7, 14, 21, and 28 days. In each examination, the following parameters were recorded:

1. Area of corneal epithelial loss (corneal erosion): The average horizontal and vertical linear dimensions of the epithelial defect as stained by locally applied fluorescein were measured using the adjustable slit lamp beam and the area computed in mm².
2. Degree of corneal opacity: grade 0, clear cornea with iris details seen clearly; grade 1, mild blurring of iris details; grade 2, moderate opacity with blurred iris crypts; and grade 3, severe corneal opacity, no iris details seen.
3. Degree of iris pigmentation: grade 0, no pigmentation; grade 1, mild; grade 2, moderate; and grade 3, severe iris pigmentation.
4. Additional observations recorded included extent of eyelid and conjunctival swelling and injection; anterior chamber reaction; and, when present, hypHEMA, corneal ectasia, perforation, and resultant endophthalmitis.

Treatment Groups and Protocol

The experimental and control groups are detailed in Table 1. They differ in concentration of NM applied and in the treatment drops used. Groups 1 and 5, as well as the fellow uninjured eye in each animal, served as the controls. In group 1, examining the effect of placebo (saline) drops on injured eyes effectively served as the model for exposed but not treated eyes. These were compared with groups 2, 3, 4, and 6. In group 5, normal saline was applied in the trephine (no exposure to mustard). In this group both eyes of each animal served as experimental eyes. In the other groups, in each animal, the fellow control eye served to assess the question of possible toxicity of the treatment drops used in that animal when the drops were applied to practically healthy eyes.

Immediately after exposure to NM, 2 drops of one of the different treatment medications listed in Table 1 were administered every hour for 12 hours in both experimental and control fellow eyes. From the second day onward, until the end of the experiment at 4 weeks, drops were given seven times daily (every 2 hours). Antibiotic ointment (chloramphenicol 5%) was applied every night to all eyes throughout the experiment. Application of the drops was performed in a blind fashion with caregivers masked to the content of the bottles of medication.
Exposure to 1% NM. Initial injury and opacity were similar among the different experimental groups one day after injury. However, 4 weeks later, corneal opacity was markedly reduced in Zn/DFO- and DFO-treated eyes compared with saline-treated eyes (\(P < 0.05\), Pearson \(\chi^2\) test). Eyes treated with ZnCl\(_2\) showed a similar trend. Observers who were masked to the treatment regimen performed grading of corneal opacity according to a four-point severity scale. Data in each bar represent mean score of six eyes.

**Systemic Antioxidant Status.** Ascorbic acid (AA), a naturally occurring free radical scavenger, is normally present in blood. At 1, 7, 14, and 28 days after injury, blood samples were obtained, and systemic oxidative stress was assessed by measurement of AA dissipation. AA, the reduced form of ascorbate and the fraction of the oxidized ascorbate (dehydro-ascorbate, DHAA) were measured,\(^6\) and the ratio between them was calculated and denoted as OSAA (see equation in Fig. 8).\(^7\)

![Figure 1](image1.png)

**Figure 1.** Degree of corneal opacity after exposure to 1% NM. Initial injury and opacity were similar among the different experimental groups one day after injury. However, 4 weeks later, corneal opacity was markedly reduced in Zn/DFO- and DFO-treated eyes compared with saline-treated eyes (\(P < 0.05\), Pearson \(\chi^2\) test). Eyes treated with ZnCl\(_2\) showed a similar trend. Observers who were masked to the treatment regimen performed grading of corneal opacity according to a four-point severity scale. Data in each bar represent mean score of six eyes.

![Figure 2](image2.png)

**Figure 2.** Degree of iris pigmentation 4 to 5 weeks after exposure to 1% NM. Areas of iris pigmentation as well as areas of atrophy were treated in NM-exposed, saline-treated eyes (A) that were not present in noninjured fellow eyes (B) and were markedly reduced in NM-exposed, Zn/DFO-treated eyes (C). (D) Mean iris pigmentation score at 4 to 5 weeks after injury was significantly reduced in Zn/DFO-treated compared with saline-treated eyes, representing a 64% protective effect (\(P < 0.05\), Pearson \(\chi^2\) test). Treatment with each component of the complex separately (ZnCl\(_2\) or DFO) showed a trend for reduction in severity. Observers masked to the treatment regimen performed grading of iris pigmentation according to a four-point severity scale. Data represent mean score of six eyes.

![Figure 3](image3.png)

**Figure 3.** Degree of iris pigmentation 4 to 5 weeks after exposure to 1% NM. Areas of iris pigmentation as well as areas of atrophy were treated in NM-exposed, saline-treated eyes (A) that were not present in noninjured fellow eyes (B) and were markedly reduced in NM-exposed, Zn/DFO-treated eyes (C). (D) Mean iris pigmentation score at 4 to 5 weeks after injury was significantly reduced in Zn/DFO-treated compared with saline-treated eyes, representing a 64% protective effect (\(P < 0.05\), Pearson \(\chi^2\) test). Treatment with each component of the complex separately (ZnCl\(_2\) or DFO) showed a trend for reduction in severity. Observers masked to the treatment regimen performed grading of iris pigmentation according to a four-point severity scale. Data represent mean score of six eyes.
Histology of Ocular Structures

At 4 to 8 weeks after NM injury, eyes of two to four animals from each group were obtained for histologic examination. Eyes were enucleated and fixed in 4% paraformaldehyde. After specimens were embedded in paraffin, 4-μm sections were cut and stained with hematoxylin and eosin for histologic evaluation of injury. In a number of eyes, Prussian blue staining was performed to identify hemosiderin.

**FIGURE 4.** Iris FA at 4 to 5 weeks after exposure to 1% NM shows that iris pigmentation and atrophy differed among the treatment groups. Integrity of iris vessels was not compromised, and no leakage had occurred at that time. (A) Control (no exposure to NM); (B) 1% NM + saline; (C) 1% NM + Zn/DFO; (D) 1% NM + ZnCl₂; (E) 1% NM + DFO.

**Histology of Ocular Structures**

At 4 to 8 weeks after NM injury, eyes of two to four animals from each group were obtained for histologic examination. Eyes were enucleated and fixed in 4% paraformaldehyde. After specimens were embedded in paraffin, 4-μm sections were cut and stained with hematoxylin and eosin for histologic evaluation of injury. In a number of eyes, Prussian blue staining was performed to identify hemosiderin.

**FIGURE 5.** Prussian blue staining showed the presence of hemosiderin in anterior segment structures of eyes 4 weeks after exposure to 2% NM. (A) 2% NM + saline; (B) 2% NM + Ga/DFO; (C) 2% NM + saline; (D) 2% NM + Ga/DFO. Note markedly reduced ferritin and hemosiderin staining in Ga/DFO-treated eye compared with saline-treated. Magnification: (A, B) ×10; (C, D) ×50.

**FIGURE 6.** Iris and lens injury 4 weeks after exposure to NM. (A–C) Nonexposed, control eye; (D–F) 2% NM, saline-treated eye; (G–I) 2% NM, Ga/DFO-treated eye. Note that loss of the normal iris protrusions (rugae) and inflammatory cell infiltration in NM-exposed eyes was more severe in the saline-treated (D) than in Zn/DFO-treated (G) eye, compared with the nonexposed eye (A). Adhesions of the iris to the lens occurred in the saline-treated eye (E) but not in the control (B) or Zn/DFO-treated (H) eyes. Cataractous lens changes including epithelial necrosis and formation of morgagnian globules was also more severe in the saline-treated (E, F) than in Zn/DFO-treated (I) eyes.
Statistical Evaluation

Gradable parameters were averaged in each treatment group at the different time points. The Mann-Whitney test was used for comparison of parametric data (i.e., erosion area, IOP, OSAA), and the Pearson $\chi^2$ test was used for comparison of nonparametric data (i.e., degree of corneal opacity or degree of iris pigmentation).

RESULTS

Exposure to NM, either 1% or 2%, caused severe and long-lasting injury to ocular anterior segment structures. These findings were noted in previous reports and can be fully appreciated in the saline-treated, exposed eyes. The extent of injury was far more severe in eyes exposed to 2% NM: perforation of the cornea occurred only after exposure to this higher concentration and only during the third or fourth week after injury. Four saline-treated eyes (4/8, 50%), as opposed to two Zn/DFO-treated eyes (2/8, 25%) and only one Ga/DFO-treated eye (1/8, 12.5%), perforated. Injury to the conjunctiva and cornea in a saline-treated eye that did not perforate after exposure to 2% NM is shown in Figure 1.

 Conjunctival injury and scarring persisted for 4 weeks after exposure (Fig. 1A) and severe chronic corneal opacity and neovascularization were observed (Fig. 1B). Conjunctival and corneal injury was markedly reduced in eyes treated with Zn/DFO (group 2) and Ga/DFO (group 6), although some residual corneal opacity persisted (Fig. 1C, Ga/DFO treated eye). Histologic examination corroborated the clinical findings. As opposed to the normal corneal structure in the fellow uninjured eye (Fig. 1D), acanthosis, irregularities and some keratinization of the corneal epithelium, and infiltration of the corneal stroma by inflammatory cells, blood vessels, and hemorrhages were seen in the eye exposed to 2% NM and treated by administration of saline only (Fig. 1E). Lysis of the extracellular matrix in the superficial stroma was also observed (Fig. 1E), which may explain the higher risk for corneal ulceration and perforation in such nontreated eyes. Corneal structure, as evident by histology, was much better preserved in Ga/DFO- and Zn/DFO-treated eyes (Fig. 1F, Ga/DFO). This protective effect could already be seen and quantified clinically during the early phases after injury and treatment: the corneal epithelial erosion caused by NM was similar in size in all experimental groups at day 1 after exposure, but was significantly reduced in Zn/DFO-treated eyes at day 3 (Table 2). Eyes treated with zinc (ZnCl$_2$) or DFO alone did not significantly differ from saline-treated eyes at that time point.

Long-term visual outcome depends highly on the degree of corneal opacity that ultimately remains. On the first day after injury, during the acute phase, the average scores of corneal opacity were not statistically different among the groups (Fig. 2, left; each bar represents average of results in six eyes). However, the mean opacity score was significantly reduced 4 weeks after injury in the Zn/DFO- and DFO-treated eyes compared with saline-treated eyes (Fig. 2, right; $P < 0.05$; each bar represents the average of results in six eyes, with each eye independently graded by four masked observers). For Zn/DFO, this represents 52% protection. Mean corneal opacity score in the Zn-treated eyes was also reduced, but this difference from saline-treated eyes was not statistically significant.

Exposure to NM also caused long-term changes in iris appearance and structure. In the early postinjury period, dilation of iris vessels, iris stromal hemorrhages, and an inflammatory anterior chamber reaction were present. It was difficult, however, to quantify these findings accurately behind the edematous and opaque cornea. As corneal condition stabilized (usually within 7 to 14 days), it was possible to observe areas of iris pigmentation as well as atrophy in NM-exposed eyes (Fig. 3A) that were not present in uninjured fellow eyes (Fig. 3B). These changes were much less severe in NM-exposed eyes treated with Zn/DFO (Fig. 3C). The iris pigmentation score at 4 weeks after injury was significantly reduced (by $>60\%$) in Zn/DFO-treated eyes compared with saline-treated eyes (Fig. 3D). Again, treatment with each component of the complex separately (i.e., ZnCl$_2$ and DFO) showed a trend for reduction in severity that did not reach statistical significance (Fig. 3D; exemplified also in Fig. 4). To examine whether neovascularization of the iris occurred and whether vessel integrity was compromised after the acute injury phase, iris FA was performed at 4 to 5 weeks after exposure. As seen in Figure 4, the degree of pigmentation and atrophy differed between the treatment groups, but no leakage had occurred at that time. Histologic sections suggest that the pigmentation may be related to iris hemorrhages that occurred during the acute injury phase. Prussian blue staining showed hemosiderin in anterior segment structures of a 2% NM-exposed and saline-treated eye (Figs. 5A, 5C) that was not present in a nonexposed eye and was markedly reduced in a 2% NM-exposed and Ga/DFO-treated eye (Figs. 5B, 5D). We also observed evidence for thickening of the iris, loss of the natural posterior rugae, and formation of posterior synechia (adhesions) to the lens capsule in NM-exposed eyes treated with saline (Figs. 6D, 6E compared with Figs. 6A, 6B). Secondary cataractous lens changes occurred with the formation of morgagnian globules and lens epithelial necrosis (Figs. 6E, 6F). In Zn/DFO- and Ga/DFO-treated eyes, changes were much less severe (Figs. 6G–I).

As seen in Figure 7, IOP was elevated in all NM-injured eyes during the acute phase, peaking on day 4 after injury. The increase in IOP above nonexposed eyes was significantly reduced (by $>55\%$) in Zn/DFO- and Ga/DFO-treated compared with saline-treated eyes at this time point ($P < 0.05$). A plot of IOP that was performed in NM-injured, saline-treated eyes at 6 to 7 weeks after injury showed that retinal function was not affected by the anterior chemical injury: dark-adapted mixed rod-cone responses, rod responses, and light-adapted cone responses (at 1- and 30-Hz flicker) did not differ between NM-injured and fellow control eyes (results not shown). This is in accord with previous observations that posterior segment involvement in mustard-induced injury is rare. Treatment with Zn/DFO did not alter the ERG responses either, testifying to the safety of this complex (data not shown).

The level of oxidative stress associated with NM injury was assessed by measuring the dissipation of AA, an antioxidant and free radical scavenger, in systemic blood throughout the experimental period. Even though the eye (a relatively small organ) was affected, in saline-treated animals marked depletion of systemic AA occurred, supporting the role of free radical formation induced by exposure to NM (Fig. 8). AA levels were better preserved in eyes treated with Zn/DFO, indicating that the formation of free radicals was at least partially inhibited by this treatment. Ga/DFO had an identical effect.

DISCUSSION

Acute and chronic injury to anterior segment eye tissues after exposure to mustard agents is well documented in human subjects, as well as in animal models. To date, no specific effective treatment is available to reduce such ocular damage. Current regimens of treatment after ocular exposure to mustard chemicals are nonspecific and do not address the basic pathophysiology underlying the injury. Treatments include use of protective gear, removal of victims from contaminated areas, copious ocular irrigation, systemic analgesics in severe cases, application of mydriatic drugs to relieve ciliary muscle spasm and prevent formation of iris adhesions, antibiotic drops to
prevent secondary bacterial infection, medications to control IOP, and use of lubricants. Some animal studies promote the topical use of corticosteroids and nonsteroidal anti-inflammatory drugs (diclofenac), colchicine, and a calcium-blocker (diltiazem) to reduce ocular inflammation. Reduced dermal and systemic injury, in animal models, was reported after treatment with thiosulfate, nicotinamide, flavonoids, and recently with topically applied iodine. However, no specific antidote or highly effective treatment against mustard toxicity is currently available.

In the present study, we have demonstrated that topical application of low concentrations of Zn/DFO or Ga/DFO, after corneal exposure to NM, markedly reduced conjunctival, corneal, iris, and anterior chamber injury. In the cornea, faster healing of epithelial erosions, reduced long-term opacification and lower levels of neovascularization were observed. In the anterior chamber, decreased inflammation and better maintenance of IOP was achieved. Iris pigmentation and atrophy were not as severe, with less posterior adhesions of the iris to the lens. Cataractous changes were also notably milder.

It is assumed that NM injury, at least in part, is mediated by the formation of ROS, in addition to its action as an alkylating agent. Oxidative stress after ocular exposure to mustard has also been observed in other clinical studies and in animal models. Subcutaneous injection of a sulfur mustard analogue in mice increased the activity of several enzymes including glucose-6-phosphate dehydrogenase and glutathione S-transferases. Dermally applied sulfur mustard caused systemic oxidative stress, raising the suggestion that flavonoids may help reduce toxicity. The marked depletion of systemic AA in the saline-treated group and the protective effect of Zn/DFO and Ga/DFO found in the present study lend further credence to this hypothesis.

We postulate that the protective effect of the complexes is the result of suppressed formation of ROS. The ability of these novel complexes to act through a combined push–pull mechanism to achieve such a reduction in free radical formation is supported by both theoretical considerations and previously reported experimental findings. We have shown that Zn/DFO and Ga/DFO—exerts its protective effect by intervening in this critical step of hydroxyl radical formation. The two components of each of these complexes, when present at or near the site of injury, will ameliorate the availability and catalytic activity of the redox-active metal ions through the push–pull mechanisms. In a number of experimental models, in which the formation of ROS plays a key role, Zn/DFO and Ga/DFO were indeed shown to afford marked protection against injury and inhibit the formation of free radicals. Thus, ischemia and reperfusion injury to the retina and heart were markedly reduced after systemic administration of either complex, as was the degree of corneal damage after topical use of Zn/DFO in alkali injury. Similarly, protection against the harmful effects of ionizing radiation was demonstrated.

The concern that mustard chemical warfare agents will be used in future terrorist acts or on the battlefield is quite real. In view of the marked protective effect observed in the present study, it is our opinion that the topical use of Zn/DFO or Ga/DFO should be considered as a basis for possible treatment of exposed human subjects. No ocular toxicity of the complexes themselves was observed. They were shown to be safe.
when used systemically and topically in this and in other experimental models of ocular injury.\textsuperscript{13-15} It should be stressed, however, that treatment with the complexes did not completely ameliorate mustard-induced injury in our model. Moreover, follow-up in the present report was relatively short, whereas sequelae of mustard injury can continue for years. These are issues that require further study. Effectiveness may be improved by using a preparation that would allow increased residence time of the active complexes on the ocular surface. Such a preparation may also be useful in the treatment of exposed skin. In addition, preconditioning (initiating treatment shortly before potential exposure) may provide further benefit. Testing the efficacy of this treatment after exposure to sulfur mustard aerosol, rather than NM, is also a necessary step before this proposed treatment can be generally recommended.

In summary, our findings indicate clear advantages concurrent with low toxicity of Zn/DFO and Ga/DFO in treatment of mustard injuries.

**Acknowledgments**

The authors thank Nahum Kitrossky and Israel Barzel for excellent technical assistance.

**References**